{
    "clinical_study": {
        "@rank": "92546", 
        "arm_group": {
            "arm_group_label": "Deep Venous Thrombosis (DVT)", 
            "description": "DVT diagnosed by imaging technique with a low or moderate Wells score"
        }, 
        "biospec_descr": {
            "textblock": "Plasma samples"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Measurement of D-Di (D-Dimer) levels using the in-vitro diagnostic reagent STA\u00ae - Liatest\u00ae\n      D-Di and STA\u00ae - Liatest\u00ae D-Di PLUS in plasma samples from patients diagnosed with Deep Vein\n      Thrombosis (DVT) Data from this study may be used in conjunction with data from the\n      prospective study entitled \"STA\u00ae - Liatest\u00ae D-Di - Exclusion of Venous Thromboembolism\n      (VTE)\", NCT01221805, the DiET study,"
        }, 
        "brief_title": "Measurement of D-Dimer Levels in Patients With Confirmed Deep Vein Thrombosis", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Deep Venous Thrombosis", 
        "condition_browse": {
            "mesh_term": [
                "Thrombosis", 
                "Venous Thrombosis", 
                "Venous Thromboembolism"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The study population tested will be recruited from ambulatory outpatients (presenting\n             at the emergency unit or outpatient clinic) suspected of having DVT.\n\n          -  Patient is < 80 years old.\n\n          -  Patient presenting at least one of these symptoms indicative of proximal DVT: leg\n             pain, tenderness (discomfort through palpation), leg swelling and /or edema,\n\n          -  Patient has confirmed proximal DVT by imaging\n\n          -  Low or moderate Wells score\n\n          -  Patient provides written informed consent to participate in the sample collection\n\n        Exclusion Criteria:\n\n          -  Patient presenting with a condition that may be associated with increased D-dimer\n             levels, even in the absence of VTE, such as:\n\n               1. Fibrinolytic therapy within the previous seven (7) days,\n\n               2. Bone fracture or surgery (with general anesthesia longer than thirty (30)\n                  minutes) within the previous one (1) month,\n\n               3. Deep hematoma diagnosed by imaging techniques within the previous one (1) month,\n\n               4. Disseminated malignancies and active cancer (active cancer defined as: cancer\n                  for which therapeutic or palliative treatment is either ongoing at the time of\n                  enrolment or has stopped less than six (6) months before enrolment),\n\n               5. Sepsis, severe infections, pneumonia within the previous 1 month,\n\n               6. Known liver cirrhosis,\n\n               7. Pregnancy or post-partum within the previous 1 month,\n\n               8. Atherosclerotic vascular disease thrombosis within the previous 1month (e.g.\n                  myocardial infarction, stroke, coronary syndrome, peripheral artery disease\n                  stage III or IV),\n\n               9. Sickle cell disease,\n\n          -  Patients presenting with a suspect thrombotic event related to catheter implantation\n\n          -  Ongoing therapeutic anticoagulants (curative and preventive treatment) starting\n             twenty four (24) hours or more before the blood drawing for D-dimer testing"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with proximal DVT diagnosed by imaging technique and with a low and moderate\n        Wells score"
            }
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02078154", 
            "org_study_id": "D-Dimer DVT"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "D-Dimer", 
            "DVT", 
            "Wells score"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Oklahoma City", 
                    "country": "United States", 
                    "state": "Oklahoma", 
                    "zip": "73104"
                }, 
                "name": "The University of Oklahoma Health Sciences Center"
            }, 
            "investigator": {
                "last_name": "Suman Wasan Rathbun, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Measurement of D-Dimer Levels in Patients With Confirmed Deep Vein Thrombosis", 
        "other_outcome": {
            "description": "Prospective, ambulatory outpatients (presenting to the emergency unit or outpatient clinic) suspected of having DVT, with a proximal positive imaging results, will be screened for eligibility using the inclusion and exclusion criteria (see Section above). Then the eligible patients will be evaluated using the Wells score and only patient with Low or moderate PTP will receive full explanation concerning nature, objectives and risks associated to the participation in this study. Written informed consent will be obtained from each participating subject prior blood drawing, processing, plasma aliquoting and freezing at -80\u00b0C for D-Dimer testing (STA Liatest DDi or STA Liatest DDi Plus to investigate unmatched results). The whole process, starting from the moment the patient is diagnosed with DVT, should not exceed 24 hours", 
            "measure": "Plasma bank for DDi measurements", 
            "safety_issue": "No", 
            "time_frame": "At the initial visit (up to 24 hours)"
        }, 
        "overall_contact": {
            "email": "suman-rathbun@ouhsc.edu", 
            "last_name": "SUMAN WASAN RATHBUN, MD", 
            "phone": "405-271-4742"
        }, 
        "overall_official": {
            "affiliation": "University of Oklahoma Health Sciences", 
            "last_name": "Suman Wasan Rathbun, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Prospective, ambulatory outpatients (presenting to the emergency unit or outpatient clinic) suspected of having DVT, with a proximal positive imaging results, will be screened for eligibility using the inclusion and exclusion criteria (see Section above). Then the eligible patients will be evaluated using the Wells score and only patient with Low or moderate Pre-Test Probability (PTP) will receive full explanation concerning nature, objectives and risks associated to the participation in this study. Written informed consent will be obtained from each participating subject prior blood drawing, processing, plasma aliquoting and freezing at -80\u00b0C for D-Dimer testing (STA Liatest DDi). The whole process, starting from the moment the patient is diagnosed with DVT, should not exceed 24 hours.", 
            "measure": "STA Liatest DDi results in DVT positive cases", 
            "safety_issue": "No", 
            "time_frame": "At the initial visit (up to 24 hours)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02078154"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Prospective, ambulatory outpatients (presenting to the emergency unit or outpatient clinic) suspected of having DVT, with a proximal positive imaging results, will be screened for eligibility using the inclusion and exclusion criteria (see Section above). Then the eligible patients will be evaluated using the Wells score and only patient with Low or moderate PTP will receive full explanation concerning nature, objectives and risks associated to the participation in this study. Written informed consent will be obtained from each participating subject prior blood drawing, processing, plasma aliquoting and freezing at -80\u00b0C for D-Dimer testing (STA Liatest DDi Plus). The whole process, starting from the moment the patient is diagnosed with DVT, should not exceed 24 hours", 
            "measure": "STA Liatest DDi Versus STA Liatest DDi Plus", 
            "safety_issue": "No", 
            "time_frame": "At the initial visit (up to 24 hours)"
        }, 
        "source": "Diagnostica Stago", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Diagnostica Stago", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}